Tirzepatide produced about 22 percent body weight loss at the highest dose in trials, the largest of any approved weight-management drug. Even so, the spread between patients is large. Two SNPs explain a meaningful chunk of that variation: one in GLP1R that affects every drug in this class, and one in GIPR that is unique to tirzepatide and other GIP-active agents.
Severe abdominal pain radiating to the back, persistent vomiting, or signs of pancreatitis warrant immediate medical attention. A history of medullary thyroid carcinoma or MEN2 is a contraindication for any incretin agonist.
Tirzepatide is titrated from 2.5 mg to a maximum of 15 mg over several months. If GI side effects forced a hold or step-back during titration, you may not have reached the dose where most of the weight loss happens. The GIPR variant is the most common genetic reason for severe early-titration nausea.
Liquid calories, late-night eating, and high-volume snacking can offset much of the satiety effect of any incretin agonist. If your eating pattern leans heavily on these, dose alone can't compensate.
Steroids, lithium, certain antidepressants, and untreated hypothyroidism or PCOS can mask or offset the weight-loss effect. Worth ruling out before concluding the drug isn't working.
Tirzepatide is a dual GLP-1 / GIP receptor agonist. Both pathways have a clinically relevant pharmacogenetic signal.
GLP1R rs10305420 (Pro7Leu) changes how efficiently the GLP-1 receptor reaches the cell surface. Leu7 carriers tend to have slightly greater weight loss and modestly higher nausea risk on any GLP-1-active drug, including tirzepatide.
GIPR rs1800437 (Glu354Gln) reduces GIP-receptor function. Carriers of the Gln354 allele have about 1.8-fold higher odds of moderate-to-severe nausea or vomiting on tirzepatide. This effect is unique to tirzepatide and other GIP-active agents and does not apply to GLP-1-only drugs like semaglutide.
If you struggled with severe nausea on tirzepatide, the GIPR variant is the most likely genetic explanation. The practical takeaway is that switching to a GLP-1-only agonist (semaglutide) often resolves the problem because the GIPR pathway isn't engaged.
Most useful if tirzepatide nausea was severe enough that you stopped, or if you've been at the maintenance dose for 8 to 12 weeks without meaningful weight loss. The GIPR result in particular is directly actionable.
Learn how genetics may affect your response to these related medications:
Possibly yes, especially if you carry the GIPR Gln354 variant. Mounjaro and Zepbound activate both GLP-1 and GIP receptors. The GIPR variant only affects drugs that hit GIP, so semaglutide (Ozempic / Wegovy) is unaffected. Plenty of patients who couldn't tolerate tirzepatide do fine on semaglutide.
On average, semaglutide produces somewhat less weight loss than tirzepatide at maximum doses (around 15 to 17 percent versus 20 percent or more). But losing 15 percent on a drug you can take is a much better outcome than 0 percent on one you can't tolerate.
It's one of the better-characterized genetic explanations for differential tolerability between people. Allele frequency varies across populations, but carriers of Gln354 are common enough that many family members or friends will have very different tirzepatide experiences.
Find out how your DNA may influence your response to Tirzepatide and other medications with a Gene2Rx pharmacogenetics report.
Get Your Report Try Our Free Calculator